Myelopeptide-2 (MP-2) Mechanisms, Clinical Applications, and

Myelopeptide-2 (MP-2): Mechanisms, Clinical Applications, and Research Perspectives in Immunomodulation
Introduction [Related: (s)-ibuprofen]
Myelopeptide-2 (MP-2) is a synthetic immunomodulatory peptide originally isolated from human bone marrow. It belongs to the family of myelopeptides, which are endogenous regulatory peptides known for their role in modulating immune responses. MP-2, with the amino acid sequence Lys-Glu-Asp-Trp-Phe-Glu-Arg, has garnered significant interest due to its ability to influence cytokine production, regulate immune cell proliferation, and modulate inflammatory responses (Klimovich et al., 2002, Immunology Letters). The peptide’s mechanism of action is multifaceted, involving the modulation of T-cell and macrophage activity, as well as the inhibition of pro-inflammatory cytokines such as TNF-α and IL-1β (Guryanova et al., 2004, Bulletin of Experimental Biology and Medicine).
MP-2’s immunoregulatory properties position it as a promising candidate for therapeutic intervention in a range of pathological conditions, including autoimmune diseases, chronic inflammation, and cancer. This paper provides a comprehensive review of MP-2, focusing on its mechanism of action, clinical value, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions. [Related: clozapine n oxide]
Clinical Value and Applications [Related: trichostatin a supplement]
The clinical value of Myelopeptide-2 lies in its potent immunomodulatory effects, which have been demonstrated in both preclinical and early clinical studies. MP-2 has shown efficacy in downregulating excessive inflammatory responses, thereby mitigating tissue damage in autoimmune and inflammatory diseases (Klimovich et al., 2002). Its ability to suppress the secretion of pro-inflammatory cytokines while enhancing anti-inflammatory cytokine production is particularly relevant in conditions characterized by immune dysregulation, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease (Guryanova et al., 2004).
In oncology, MP-2 has been investigated for its capacity to modulate the tumor microenvironment. By inhibiting the production of immunosuppressive cytokines and enhancing cytotoxic T-cell activity, MP-2 may contribute to improved anti-tumor immune responses (Klimovich et al., 2002). Furthermore, its role in hematopoiesis and bone marrow recovery suggests potential applications in supportive care for patients undergoing chemotherapy or bone marrow transplantation (Klimovich et al., 2002; Guryanova et al., 2004).
Emerging evidence also points to the utility of MP-2 in infectious diseases, where it may help restore immune homeostasis and prevent the progression of sepsis or chronic infections (Klimovich et al., 2002). Collectively, these findings underscore the broad clinical potential of MP-2 as an immunotherapeutic agent.
Key Challenges and Pain Points Addressed
Current immunomodulatory therapies, such as corticosteroids, biologics, and small molecule inhibitors, are associated with significant limitations, including systemic immunosuppression, increased risk of infections, and adverse metabolic effects (Smolen et al., 2016, Lancet). These challenges highlight the need for targeted immunomodulators that can restore immune balance without compromising host defense.
MP-2 addresses several key pain points in existing treatments:
1. **Selective Immunomodulation:** Unlike broad-spectrum immunosuppressants, MP-2 selectively modulates immune responses, reducing pathological inflammation while preserving protective immunity (Guryanova et al., 2004).
2. **Reduced Adverse Effects:** Preclinical studies indicate a favorable safety profile, with minimal off-target effects and low toxicity (Klimovich et al., 2002).
3. **Support for Hematopoiesis:** MP-2 promotes bone marrow recovery and hematopoietic function, which is particularly beneficial in patients undergoing cytotoxic therapies (Klimovich et al., 2002).
4. **Potential for Combination Therapy:** MP-2’s mechanism of action allows for synergistic use with existing immunotherapies, potentially enhancing efficacy while minimizing adverse effects (Guryanova et al., 2004).
By addressing these challenges, MP-2 represents a promising advancement in the field of immunomodulation.
Literature Review
A growing body of literature supports the immunomodulatory and therapeutic potential of Myelopeptide-2. Key studies include:
1. **Klimovich et al. (2002, Immunology Letters):** This foundational study characterized the immunoregulatory effects of MP-2, demonstrating its ability to inhibit pro-inflammatory cytokine production and modulate T-cell activity in vitro and in vivo.
2. **Guryanova et al. (2004, Bulletin of Experimental Biology and Medicine):** The authors investigated the effects of MP-2 on hematopoiesis and immune cell proliferation, reporting enhanced bone marrow recovery and improved immune function in animal models.
3. **Klimovich et al. (2003, Immunology):** This study explored the role of MP-2 in cancer immunotherapy, showing that MP-2 administration led to increased cytotoxic T-cell activity and reduced tumor growth in murine models.
4. **Ivanova et al. (2005, Journal of Peptide Science):** The pharmacokinetics and stability of MP-2 were evaluated, revealing favorable bioavailability and resistance to proteolytic degradation.
5. **Smolen et al. (2016, Lancet):** While not specific to MP-2, this review highlights the limitations of current immunomodulatory therapies and the need for novel agents such as MP-2.
6. **Petrov et al. (2007, Clinical Immunology):** The authors assessed the safety and tolerability of MP-2 in a phase I clinical trial, reporting no serious adverse events and preliminary evidence of immunomodulatory activity.
7. **Zaitseva et al. (2010, International Immunopharmacology):** This study examined the synergistic effects of MP-2 with other immunotherapies, suggesting potential benefits in combination regimens.
Collectively, these studies provide a robust foundation for the continued investigation of MP-2 in both preclinical and clinical settings.
Experimental Data and Results
Experimental investigations of MP-2 have focused on its immunomodulatory effects, safety profile, and therapeutic efficacy in various disease models.
**In vitro studies** have demonstrated that MP-2 inhibits the production of TNF-α, IL-1β, and IL-6 in activated macrophages, while simultaneously increasing the secretion of anti-inflammatory cytokines such as IL-10 (Klimovich et al., 2002). MP-2 also suppresses the proliferation of autoreactive T-cells, thereby reducing the risk of autoimmune pathology (Guryanova et al., 2004).
**In vivo studies** in murine models of autoimmune disease have shown that MP-2 administration leads to a significant reduction in clinical disease scores, decreased inflammatory infiltrates in target tissues, and improved survival rates (Klimovich et al., 2002; Guryanova et al., 2004). In cancer models, MP-2 enhances the cytotoxic activity of CD8+ T-cells and natural killer (NK) cells, resulting in reduced tumor burden and prolonged survival (Klimovich et al., 2003).
**Safety and pharmacokinetic studies** indicate that MP-2 is well-tolerated at therapeutic doses, with no evidence of systemic toxicity or immunosuppression (Ivanova et al., 2005; Petrov et al., 2007). The peptide exhibits favorable pharmacokinetics, with a plasma half-life suitable for once-daily administration and minimal degradation by serum proteases.
**Clinical data** from early-phase trials suggest that MP-2 is safe and may confer immunomodulatory benefits in patients with autoimmune and inflammatory diseases (Petrov et al., 2007). However, larger randomized controlled trials are needed to confirm these findings and establish efficacy in specific indications.
Usage Guidelines and Best Practices
Based on available preclinical and clinical data, the following usage guidelines are recommended for MP-2:
1. **Dosage and Administration:** MP-2 is typically administered via subcutaneous or intravenous injection. Preclinical studies have used doses ranging from 0.1 to 1 mg/kg, with once-daily administration demonstrating optimal efficacy (Klimovich et al., 2002; Guryanova et al., 2004).
2. **Patient Selection:** MP-2 may be considered for patients with autoimmune diseases, chronic inflammatory conditions, or as an adjunct in cancer immunotherapy. Patient selection should be guided by disease severity, prior treatment history, and risk of immunosuppression.
3. **Monitoring:** Regular monitoring of immune function, cytokine profiles, and hematological parameters is recommended to assess therapeutic response and detect potential adverse effects.
4. **Combination Therapy:** MP-2 may be used in combination with other immunomodulatory agents, provided that potential drug-drug interactions are carefully evaluated (Zaitseva et al., 2010).
5. **Contraindications:** Caution is advised in patients with active infections or severe immunodeficiency, as the immunomodulatory effects of MP-2 may alter host defense mechanisms.
Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 29 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11578148